Drug profile · INN
ribociclib succinate
KISQALI
ribociclib succinate (KISQALI) is a cyclin-dependent kinase 4 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — ribociclib succinate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 7
- Data quality
- 0.84
Quick answer
ribociclib succinate (KISQALI) is a cyclin-dependent kinase 4 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Cyclin-dependent kinase 4 inhibitor
Primary target: Cyclin-dependent kinase 4
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ribociclib succinate?
ribociclib succinate (KISQALI) is a cyclin-dependent kinase 4 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ribociclib succinate?
KISQALI is a marketed brand name for ribociclib succinate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ribociclib succinate?
ribociclib succinate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.